9 January 2020 - Deborah Wilkes
Strides Pharma Science has a new chief, The Carlyle Group has taken on Ian Read, and GlaxoSmithKline (GSK) has a new member of its Corporate Executive Team.
Strides appoints new chief
Strides Pharma Science has appointed Cipla’s R Ananthanarayanan as chief executive officer and managing director with effect from 09 January 2020.
Ananthanarayanan will take over from founder Arun Kumar, who will become chairman on 1 April 2020.
The Indian company said Ananthanarayanan had “over three decades of top pedigree global pharmaceutical experience”.
Up until recently, he was global chief operating officer at Cipla where he was responsible for the company’s generics business in regulated markets and branded generics in emerging markets. He has also worked for Teva Pharmaceutical Industries in the US as well as Dr Reddy’s Laboratories, Piramal Healthcare, Galpharm International and Zydus Cadila.
Commenting on the appointment, Kumar said Strides would benefit significantly from Ananthanarayanan’s “leadership experience, industry perspective, technical knowledge and business acumen”.
Ian Read takes position at Carlyle
The Carlyle Group has taken on Ian Read – former chairman and chief executive officer of Pfizer – as an operating executive in its Global Healthcare Group.
The private-equity firm said Read would help find “compelling investment opportunities” and “build, grow and transform companies”.
Carlyle added that Read would provide its healthcare portfolio companies with advice on growth strategies, leadership and talent development, effective operations and risk management.
He joins a team of around 50 operating executives at Carlyle.
Carlyle’s healthcare portfolio includes Albany Molecular Research, iNova Pharmaceuticals and PPD.
Read is also set to join the board of Viatris, the new company that will be formed from the planned combination of Mylan and Pfizer’s Upjohn business (click here to read the News story).
News from GSK
GSK has announced that Deborah Waterhouse – chief executive officer of HIV specialist ViiV Healthcare – has joined its Corporate Executive Team with immediate effect.
ViiV Healthcare is majority owned by GSK, with Pfizer and Shionogi as shareholders.
Waterhouse joined GSK in 1996 and has worked in a number of leadership roles in Europe, Asia-Pacific and the US.